Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 6 | 3 |
| List of Tables | 8 | 1 |
| Biodefense Industry Introduction | 9 | 1 |
| Biodefense Industry Regulatory Environment | 10 | 2 |
| Regulatory Agencies | 10 | 1 |
| Food and Drug Administration | 10 | 1 |
| FDA Counterterrorism Programs | 10 | 1 |
| Project Bioshield | 10 | 2 |
| Biodefense Industry Pathogens and Pipeline | 12 | 9 |
| Anthrax | 12 | 1 |
| Introduction | 12 | 1 |
| Treatment Options | 12 | 1 |
| Vaccines | 12 | 1 |
| Therapeutics | 12 | 1 |
| Anthrax Product Pipeline Analysis | 13 | 1 |
| Smallpox | 14 | 1 |
| Introduction | 14 | 1 |
| Treatment Options | 14 | 1 |
| Vaccines | 14 | 1 |
| Therapeutics | 14 | 1 |
| Smallpox Product Pipeline Analysis | 15 | 1 |
| Viral Hemorrhagic Fevers | 16 | 1 |
| Introduction | 16 | 1 |
| Treatment Options | 17 | 1 |
| Vaccines | 17 | 1 |
| Therapeutics | 17 | 1 |
| Viral Hemorrhagic Fevers Product Pipeline Analysis | 17 | 2 |
| Plague | 19 | 1 |
| Introduction | 19 | 1 |
| Treatment Options | 19 | 1 |
| Vaccines | 19 | 1 |
| Therapeutics | 19 | 1 |
| Plague Product Pipeline Analysis | 19 | 1 |
| Tularemia | 20 | 1 |
| Introduction | 20 | 1 |
| Treatment Options | 20 | 1 |
| Vaccines | 20 | 1 |
| Therapeutics | 20 | 1 |
| Tularemia Product Pipeline Analysis | 20 | 1 |
| Biodefense Industry Funding | 21 | 8 |
| Introduction | 21 | 1 |
| Biodefense Funding The US | 21 | 1 |
| Department of Health and Human Services | 21 | 1 |
| Biomedical Research and Development Authority | 21 | 1 |
| NIH Challenge Grants in Health and Science Research | 22 | 1 |
| NIH Cooperative Research and Development Agreement (CRADA) | 22 | 1 |
| NIH Small Business Biodefense Program Awards | 22 | 1 |
| Purpose | 22 | 1 |
| Mechanism of Support | 22 | 1 |
| Budget and Period | 22 | 1 |
| Regional Centers of Excellence for Biodefense and Emerging Infectious Diseases | 23 | 1 |
| Great Lakes Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (GLRCE) | 23 | 1 |
| Mid-Atlantic Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (MARCE) | 23 | 1 |
| Midwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (MRCE) | 24 | 1 |
| New England Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (NERCE) | 24 | 1 |
| Northeast Biodefense Center (NBC) | 24 | 1 |
| Northwest Regional Center of Excellence for Biodefense and Emerging Infectious Diseases Research (NWRCE) | 24 | 1 |
| Pacific Northwest Regional Center of Excellence (PNWRCE) | 25 | 1 |
| Pacific-Southwest Regional Center of Excellence (PSW RCE) | 25 | 1 |
| Rocky Mountain Regional Center of Excellence (RMRCE) | 25 | 1 |
| Southeast Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (SERCEB) | 25 | 1 |
| Western Regional Center of Excellence for Biodefense and Emerging Infectious Diseases (WRCE) | 26 | 1 |
| Defense Threat Reduction Agency (DTRA) | 26 | 1 |
| DTRA Funded Projects | 26 | 1 |
| US Army Medical Research Institute of Infectious Diseases (USAMRIID) | 27 | 1 |
| Technology Transfer | 27 | 1 |
| Defense Advanced Research Projects Agency (DARPA) | 27 | 1 |
| Biodefense Funding Europe | 27 | 1 |
| EU Biodefense Programs | 27 | 1 |
| European Defense Agency (EDA) | 27 | 1 |
| Bio-Edep | 27 | 1 |
| New and Emerging Science and Technology (NEST) | 28 | 1 |
| Health Protection Agency (HPA) | 28 | 1 |
| Funding | 28 | 1 |
| Biodefense Industry Case Study | 29 | 2 |
| Case Study Anthrax Contamination | 29 | 1 |
| Company Sabre Technical Services LLC | 29 | 1 |
| Solution Facility Decontamination with Chlorine Dioxide (ClO2) Gas | 29 | 1 |
| Background | 29 | 1 |
| Engagement | 29 | 1 |
| Sampling Exercise | 29 | 1 |
| Decontamination | 30 | 1 |
| Biodefense Industry Competitive Landscape | 31 | 13 |
| Achaogen | 31 | 1 |
| Biodefense Contracts | 31 | 1 |
| Achaogen Receives $64m Contract from BARDA for the Development of ACHN-490, 30-Aug-2010 | 31 | 1 |
| Alnylam Pharmaceuticals | 31 | 1 |
| Biodefense Contracts | 31 | 1 |
| Alnylam Biodefense Deal Renewed | 31 | 1 |
| Bavarian Nordic | 32 | 1 |
| Biodefense Contracts | 32 | 1 |
| Bavarian Nordic Receives $25m Milestone Payment After Scaling up for Industrial Production of IMVAMUNE, 28-Oct-2011 | 32 | 1 |
| Bavarian Nordic Signs Contracts with Denmark and Another European NATO Country for Delivery of IMVAMUNE Smallpox Vaccine, 15-Jun-2011 | 32 | 1 |
| Bavarian Nordic Announces Contract for the Development of a Freeze-Dried Version of IMVAMUNE Smallpox Vaccine, Extended to Total Value of $94m, 11-Apr-2011 | 32 | 1 |
| Cleveland BioLabs | 33 | 1 |
| Biodefense Contracts | 33 | 1 |
| Department of Defense Increases Development Contract with Cleveland for CBLB502, 30-Jun-2011 | 33 | 1 |
| Cleveland BioLabs Wins $1.6m Development Contract from Defense Threat Reduction Agency of the Department of Defense for CBLB502, 25-Jan-2011 | 33 | 1 |
| Dynavax Technologies Inc. | 34 | 1 |
| Biodefense Contracts | 34 | 1 |
| Dynavax Awarded NIH Grant to Explore Feasibility of Universal Papilloma Virus Vaccine, 06-Jul-2010 | 34 | 1 |
| Dynport Vaccine Company LLC (DVC) | 34 | 1 |
| Biodefense Contracts | 34 | 1 |
| CSC s DVC Wins $32.3m NIAID Contract to Establish Phase I Clinical Trial Unit, 14-Jul-2008 | 34 | 1 |
| CSC s DVC to Continue Plague Vaccine Development, 05-Jun-2008 | 35 | 1 |
| Elusys Therapeutics | 35 | 1 |
| Biodefense Contracts | 35 | 1 |
| Elusys Receives $68m Contract to Develop Anthim for Intramuscular Pre- and Post-Exposure Prophylaxis of Anthrax Infection, 08-Sep-2011 | 35 | 1 |
| Elusys Awarded an Additional $40.6m Under Existing US Government Contract to Fund Advanced Development of Anthim, 04-Aug-2010 | 36 | 1 |
| Elusys Receives Contract for up to $143m from the US Federal Government to Fund Advanced Development of Anthim, a New Treatment for Anthrax, 04-Jan-2010 | 36 | 1 |
| Emergent BioSolutions | 36 | 1 |
| Biodefense Contracts | 37 | 1 |
| Emergent Receives Award to Supply 44.75 million Doses of BioThrax to the US Government Over Five Years, 03-Oct-2011 | 37 | 1 |
| The US Government Issues a Request for Proposal for Supply of 44.7 million Doses of Emergent s BioThrax Over the Next Five Years, 26-May-2011 | 37 | 1 |
| The US Government Expands BioThrax s Procurement Contract to 17.9 million Doses from 14.5 million, Increasing the Contract Value by up to $101m, 02-May-2011 | 37 | 1 |
| Emergent BioSolutions Receives Five Therapeutic Discovery Project Grants, 09-Nov-2010 | 37 | 1 |
| Emergent BioSolutions Awarded HHS Contract Valued at up to $186.6m to Develop rPA Anthrax Vaccine, 17-Sep-2010 | 37 | 1 |
| Emergent Signs $28.7m NIAID Contract for Advanced Development of Third Generation Anthrax Vaccine, 01-Sep-2010 | 38 | 1 |
| Emergent BioSolutions Awarded HHS Contract Valued at up to $107m to Develop Large-Scale Manufacturing for BioThrax, 14-Jul-2010 | 38 | 1 |
| Ichor Medical Systems | 39 | 1 |
| Biodefense Contracts | 39 | 1 |
| Ichor Receives $2.2m Federal Contract to Develop Vaccine for Biodefense Pathogen, 26-Jul-2010 | 39 | 1 |
| Nanotherapeutics | 39 | 1 |
| Biodefense Contracts | 39 | 1 |
| Nanotherapeutics Awarded $30.9m NIAID Contract to Develop Inhaled Antiviral for Prophylaxis and Treatment of Smallpox, 24-Aug-2009 | 39 | 1 |
| PharmAthene | 40 | 1 |
| Biodefense Contracts | 40 | 1 |
| PharmAthene Receives a $5.7m Contract from the Department of Defense for Nerve Agent Medical Countermeasure Program, 16-Aug-2011 | 40 | 1 |
| PharmAthene Receives Four Therapeutic Discovery Project Grants Totaling Approximately $850,000, 04-Nov-2010 | 40 | 1 |
| PharmAthene Wins Additional $78.4m in Funding for Advanced Development of SparVax Anthrax Vaccine, 23-Feb-2010 | 40 | 1 |
| SIGA Technologies | 41 | 1 |
| Biodefense Contracts | 41 | 1 |
| SIGA Technologies Receives $7.7m Grant for the Development of Antiviral Drugs for Arena Viruses, 24-Aug-2011 | 41 | 1 |
| SIGA to Sell 1.7 million Courses of ST-246 to National Stockpile Under Modified BARDA Contract, 27-Jun-2011 | 41 | 1 |
| SIGA Technologies Receives US Government Contract Valued at up to $2.8 billion, 13-May-2011 | 41 | 1 |
| BARDA Supports Project BioShield Contract for Smallpox Drug, 13-May-2011 | 42 | 1 |
| SIGA Awarded $2.8m Contract for the Development of a Broad Spectrum Antiviral Drug, 25-Feb-2010 | 42 | 1 |
| SIGA Technologies Receives a $3m Research Grant from the NIH, 02-Sep-2009 | 42 | 1 |
| SIGA Technologies Receives Additional $20m from the NIH for ST-246 Antiviral Therapeutic Development, 18-Sep-2008 | 42 | 1 |
| Federal Government Awards SIGA Technologies $55m to Develop Broader Applications for its Lead Drug Candidate ST-246 | 43 | 1 |
| XOMA | 43 | 1 |
| Biodefense Contracts | 43 | 1 |
| XOMA Secures a Federal Contract to Expand its Next-Generation Human Botulism Antitoxin Portfolio, 03-Oct-2011 | 43 | 1 |
| Biodefense Industry Appendix | 44 | 6 |
| Market Definitions | 44 | 1 |
| Abbreviations | 44 | 2 |
| Bibliography | 46 | 1 |
| Research Methodology | 47 | 3 |
| Coverage | 47 | 1 |
| Secondary Research | 48 | 1 |
| Primary Research | 48 | 1 |
| Section-Wise Methodology | 48 | 1 |
| Expert Panel Validation | 49 | 1 |
| Contact Us | 49 | 1 |
| Disclaimer | 49 | 1 |
